- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
FDA Approves Biocon Biologics Ustekinumab Biosimilar, Yesintek
The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology conditions, including psoriatic arthritis and inflammatory bowel disease.
The FDA has approved Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara (ustekinumab) for the treatment of inflammatory bowel disease, plaque psoriasis, and psoriatic arthritis.1
Ustekinumab is a humanized immunoglobulin G1k (IgG1k) monoclonal antibody used to treat psoriatic arthritis, plaque psoriasis, and inflammatory bowel disease. IgG1k antibodies bind to the p40 protein subunit utilized by interleukin (IL)-12 and IL-23 cytokines. | Image credit: Steve Cukrov - stock.adobe.com
The biosimilar was developed by Karnataka, India–based Biocon Biologics and will likely launch in the second half of 2025, along with Otulfi (ustekinumab-aauz), Selarsdi (ustekinumab-aekn), Imuldosa (ustekinumab-srlf), and Pyzchiva (ustekinumab-ttwe). Wezlana (ustekinumab-auub), the first Stelara biosimilar to be approved, will launch in January 2025, per a settlement agreement with Johnson and Johnson (J&J), the maker of Stelara.2
The newest biosimilar is set to launch in the United States by February 22 at the latest, according to a settlement and licensing agreement reached earlier this year between J&J's subsidiary Janssen and Biocon Biologics.
Imuldosa was approved in October 2024,3 Otulfi was approved in September 2024, Pyzchiva was approved in July 2024, and Wezlana was approved in October 2023.4
According to the National Institute of Health, the US prevalence of PsA ranges from 6 per 100,000 to 25 per 100,000.5 Medscape estimates that between 1% to 2% of the US population has plaque psoriasis.6 Additionally, IBD affects 2.4 million to 3.1 million people in the US, with rising prevalence and health care costs, totaling $8.5 billion annually in 2018, according to the CDC.7
Biocon Biologics shared clinicals trial data on Yesintek at the European Academy of Dermatology and Venereology (EADV) 2024 Congress. The data concened a phase 3 randomized, double-blind, multicenter study evaluated the biosimilar against the reference biologic in 384 adult patients with moderate to severe chronic plaque psoriasis.8
Over 28 weeks, the primary efficacy endpoint, percentage change from baseline in Psoriasis Area and Severity Index, showed equivalence between Yesintek and Stelara. The study also confirmed comparable safety, immunogenicity, and pharmacokinetics profiles.
“This pivotal trial of [Yesintek] clearly met the safety and efficacy endpoints, thereby fulfilling the expectations set for a biosimilar. [Yesintek] offers tangible promise for all patients qualifying for treatment with Ustekinumab,” said Uwe Gudat, MD, chief medical officer, Biocon Biologics, in a statement about the trial.
References
1. U.S. FDA approves Biocon Biologics’ Yesintek™, Bmab 1200 biosimilar to J&J’s Stelara® (Ustekinumab). Press release. Biocon Biologics; December 1, 2024. Accessed December 2, 2024. https://www.bioconbiologics.com/u-s-fda-approves-biocon-biologics-yesintek-bmab-1200-biosimilar-to-jjs-stelara-ustekinumab/
2. Jeremias S. Amgen’s Stelara biosimilar delayed until 2025 after settling with J&J.The Center for Biosimilars®. May 29, 2024. Accessed December 2, 2024. https://www.centerforbiosimilars.com/view/amgen-s-stelara-biosimilar-delayed-until-2025-after-settling-with-j-j
3. Jeremias S. FDA Approves Imuldosa, a Biosimilar to Stelara. The Center for Biosimilars. October 11, 2024. Accessed December 2, 2024. https://www.centerforbiosimilars.com/view/fda-approves-imuldosa-a-biosimilar-to-stelara
4. Biosimilar approvals. The Center for Biosimilars. Updated December 2, 2024. Accessed December 2, 2024. https://www.centerforbiosimilars.com/view/fda-approves-imuldosa-a-biosimilar-to-stelara
5. Karmacharya P, Crowson CS, Bekele D, et al. The epidemiology of psoriatic arthritis over 5 decades: a population-based study. Arthritis Rheumatol. 2022;73(10):1878-1885. doi:10.1002/art.41741
6. Lui H, Mamelak AJ. Plaque psoriasis. Medscape. Updated December 21, 2023. Accessed December 2, 2024. https://emedicine.medscape.com/article/1108072-overview#:~:text=Plaque%20psoriasis%20occurs%20worldwide%2C%20although,the%20population%20has%20plaque%20psoriasis
7. IBD facts and stats. CDC. June 21, 2024. Accessed December 2, 2024. https://www.cdc.gov/inflammatory-bowel-disease/php/facts-stats/index.html
8. Biocon Biologics announces new dermatology data to be presented at EADV Congress 2024. September 25, 2024. Accessed December 2, 2024. https://www.biocon.com/biocon-biologics-announces-new-dermatology-data-to-be-presented-at-eadv-congress-2024/
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.
